NCT00080535 2018-01-29
Anti-Tac(Fv)-PE38 (LMB-2) to Treat Cutaneous T-Cell Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)